LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC (LungTech)
Lung cancer is the leading cause of cancer death worldwide with a crude incidence of lung cancer in the European Union of 52/100.000 per year and a mortality of 47/100.000 per year. Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of all cases. The five year survival of NSCLC patients is quite poor (16%), mainly due to patients being diagnosed at advanced stages. However if lung cancer can be detected and treated at an earlier stage the outcome and survival is much more favorable with five year survival rates up to 77%.
The current standard of care for small volume tumors is surgical resection in medically fit patients, consisting in lobectomy or pneumonectomy accompanied by a systematic mediastinal lymph node sampling or lymphadenectomy. For the patient population with small volume disease at early stage surgery offers the potential of local tumor control in up to 96% of the patients.
However, about one quarter of the patients is medically inoperable because of coexisting morbidities or poor general condition, mostly the result of a long smoking history and consecutive chronic Obstructive pulmonary disease (COPD) and coronary artery disease (CAD).
The main purpose of this trial is to assess the effectiveness of IG-SBRT (Image guided stereotactic body radiotherapy) in patients with medically inoperable early stage, centrally located NSCLC and in those who are not willing to undergo surgical treatment.
Secondary objectives of the study are
- to assess safety of the treatment modality by collecting data about acute and late toxicity
- patterns of local and distant recurrence and relation between the site of local recurrence and the clinical (CTV) and planning target volume (PTV)
- survival and cause of death
|Non-small Cell Lung Cancer Stage I Non-small Cell Lung Cancer Stage II||Radiation: Stereotactic Body Radiotherapy (SBRT)||Phase 2|
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||LungTech Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC: A Phase II Study in Preparation for a Randomized Phase III Trial|
- Effectiveness of SBRT in early stage centrally located tumors, ≤ 7 cm [ Time Frame: freedom from local progression rate at 3 years ]
|Study Start Date:||August 2015|
|Estimated Study Completion Date:||December 2019|
|Estimated Primary Completion Date:||December 2018 (Final data collection date for primary outcome measure)|
Experimental: Stereotactic Body Radiotherapy (SBRT)
All eligible patients will be offered Stereotactic Body Radiotherapy using Four-dimensional computed tomography (4D-CT) planning (as a minimum), delivering a dose of 60 Gy in 8 fractions of 7.5 Gy on alternate days over a planned treatment time of 2.5 weeks
Radiation: Stereotactic Body Radiotherapy (SBRT)
A form of radiation therapy, where only the primary tumor is targeted and precise stereotactic tumor localization combined with techniques reducing breathing- induced target motion allowed small safety margins. These small volumes are treated with hypo-fractionated, escalated irradiation doses. It's now further developed in multiple clinical and technological aspects e.g. FDG-PET/CT based nodal staging, respiration correlated CT- imaging for target volume definition and image-guided treatment delivery.
Other Name: Stereotactic Ablative Body Radiotherapy (SABR)
Conventionally fractionated radiotherapy (RT) has been the standard of care for medically inoperable NSCLC with prescribed doses of usually 60 - 66 Gy.This moderate irradiation regimen resulted in a local failure rate of approximately 50% and local failure- not distant - has been shown to be the most frequent pattern of disease recurrence. Still, conventional RT resulted in overall survival (OS) and cancer specific survival (CSS) superior to best supportive care, though it is clearly an insufficient treatment with CSS rates of only about 30% after 5 years.
Retrospective studies reported a dose-response relationship for local tumor control: higher irradiation doses resulted in improved rates of local tumor control which was found to translate into improved OS. Simultaneously, a dose- response relationship with a volume-effect relation has been demonstrated for radiation induced pneumonitis, being the most relevant toxicity after RT. These relations are known to apply to other organs at risk (OAR)including esophagus and spinal cord. Consequently, traditional target volume concepts conducting nodal irradiation in clinically node negative patients and traditional RT- planning and delivery techniques, with low accuracy and broad safety margins, do not allow the routine application of sufficient irradiation doses due to high toxicity rates.
In the mid-90s, after encouraging success in the treatment of cerebral malignancies, the concept of stereotactic RT was taken over from the cranium to the body. Only the primary tumor was targeted and precise stereotactic tumor localization combined with techniques reducing breathing- induced target motion allowed small safety margins. These small volumes were treated with hypo-fractionated, escalated irradiation doses. Since then, the technique of image guided (IG) -stereotactic body RT (SBRT) also known as Stereotactic Ablative Body Radiotherapy (SABR) was further developed in multiple clinical and technological aspects e.g. Fluorine-18 Fluorodeoxyglucose positron emission tomography / computed tomography (FDG-PET/CT) based nodal staging, respiration correlated CT-imaging for target volume definition and image-guided treatment delivery.
Safety and efficacy has been demonstrated in a large series of patients with stage I NSCLC. The majority of patients were medically inoperable and SBRT was practiced instead of conventionally fractionated RT. However, safety of SBRT has been demonstrated even in high risk patients with advanced age, severe COPD and very poor pulmonary function, which would have made any curative approach except SBRT difficult or even impossible. On the other side of the patient spectrum, retrospective studies suggested equivalent outcome compared to sub-lobar resection, which is confirmed by Markov modelling studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01795521
|Contact: Oussama Karroumemail@example.com|
|Cliniques Universitaires Saint-Luc||Recruiting|
|Brussels, Belgium, 1200|
|Contact: Xavier Geets, MD +32 27644719 firstname.lastname@example.org|
|Principal Investigator: Xavier Geets, MD|
|U.Z. Leuven - Campus Gasthuisberg||Recruiting|
|Leuven, Belgium, 3000|
|Contact: Stephanie Peeters, MD +32 16 341844 email@example.com|
|Principal Investigator: Stephanie Peeters, MD|
|Freiburg, Germany, 79106|
|Contact: Ursula Nestlé, MD +49 76127095390 firstname.lastname@example.org|
|Principal Investigator: Ursula Nestlé, MD|
|Wuerzburg, Germany, 97080|
|Contact: Michael Flentje +49 9312015891 Flentje_m@klinik.uni-wuerzburg.de|
|Principal Investigator: Michael Flentje, MD|
|Zurich, Switzerland, 8091|
|Contact: Matthias Guckenberger, MD +41 442552930 Matthias.Guckenberger@usz.ch|
|Principal Investigator: Matthias Guckenberger, MD|
|Royal Marsden Hospital - Sutton, Surrey||Recruiting|
|Sutton, Surrey, United Kingdom, SM2 5PT|
|Study Chair:||Nestlé Ursula||University Hospital Freiburg|